Thousands of NHS patients denied breakthrough Alzheimer’s drugs

It is estimated that around 70,000 adults in England would have been eligible for treatment if the drugs had been approved - (AP)

Two breakthrough drugs that slow the progression of Alzheimer’s disease have been refused for use on the NHS in a blow to thousands of patients.

Lecanemab and donanemab slow down the decline in Alzheimer’s patients' ability to carry out daily activities.